Recombinant Antibodies are novel antibodies produced in vitro using genetic engineering techniques. Antibody genes are cloned into expression vectors and expressed in culture systems such as mammalian cells, yeast, or bacteria, completely eliminating reliance on traditional animal immunization and hybridoma technology.
This technical approach offers multiple core advantages: Defined sequences: complete genetic information enables precise editing and optimization; Animal-free production: avoids ethical concerns and reduces the risk of pathogen contamination; Engineerability: facilitates targeted design such as humanization, fragmentation, and conjugation modifications; Rapid generation: bypasses tedious hybridoma screening, significantly shortening the production cycle.
Compared with traditional antibodies, recombinant antibodies outperform hybridoma-derived monoclonal antibodies and polyclonal antibodies in sequence transparency, degree of humanization (designable as 100% human), batch stability, and engineering flexibility. Despite relatively higher costs, they have become the preferred technical platform for therapeutic drug development, diagnostic reagent production, and customized research tools, driving antibody engineering into a new era of precise design.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.
What is this antibody validated in?
Biotin Anti-Alpha-synuclein antibody [MJFR1] (ab309388) is a rabbit recombinant monoclonal antibody and is validated for use in Immunohistochemistry (IHC-P) in Human samples.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies.
Related products
Antibody clone MJFR1 is also available pre-conjugated to a variety of labels for your convenience – Anti-Alpha-synuclein Biotin [MJFR1] (ab309388).
Other related products
We have a range of other formats of antibody clone [MJFR1] also available for your convenience:
ab138501
, Carrier free -
ab209420
, Carrier free -
ab259612
,
ab309157
, Carrier free -
ab309158
, Biotin - ab309388, HRP -
ab314243
,
ab320839
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
®
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
®
patents
.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
.
Host
Rabbit
Reactivity
Applications
sELISA
Conjugation
Biotin
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.